Corporate Performance

Lyft stock jumped this week after the ride-sharing company revised its outlook as riders slowly return.
Carl Sullivan
Analysts foresee solid growth for Apple in the long term; the near term looks good too as the pandemic shutdown drives services demand.
Chris Lange
Movie theater operator AMC Entertainment says that it may not be able to operate as a "going concern" because of the effects of the COVID-19 pandemic. What happens if all its screens go dark?
Douglas A. McIntyre
Nike doesn’t shy away from difficult subjects, and the current protest movement is no exception.
Carl Sullivan
Mark Zuckerberg won’t remove or add warning labels to posts by President Trump, and that may be an issue for some advertisers, users and employees.
Carla Baranauckas
Snap reportedly is preparing to offer a stripped-down version of its platform that partners can embed in their own apps. Could this give the stock the shot in the arm that Wall Street is looking for?
Paul Ausick
Investors look at Aytu BioScience as it looks at expanding in the COVID testing field.
Chris Lange
On Tuesday, AMD's chief financial officer laid out how the company plans to become cash-flow positive this year and generate a "significant amount of cash" over the next few years. Investors did not...
Paul Ausick
Shopify’s exponential growth has rewarded investors this year but Amazon is also powering ahead.
Chris Lange
AT&T adapts its advertising to troubled times, spending more on live news and targeting stay-at-home consumers online.
Carl Sullivan
Grubhub is reportedly seeking a breakup fee as regulators eye merger talks with Uber.
Chris Lange
Although one major food producer was slapped by a European court this week, plenty of competitors are chasing the plant-based protein market. Beyond Meat is headed for China.
Paul Ausick
Aurora Cannabis closed its acquisition of Reliva ahead of schedule but poor results from Canopy Growth may have dinged pot stocks.
Carla Baranauckas
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
Carl Sullivan
Counting out a tobacco company has never proved to be a good bet over the long term. Will this time be different?
Paul Ausick